S-1 · primary and resale
Issued 2026
Proposed maximum
Shares registered
- Filed
- Effective
VRXA$1.01-1.94%
Veraxa Biotech AG - Post de-SPAC
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: DEExchange: Nasdaq
Mkt Cap:$142.82M
Float & O/S:
Inst Own:
DilutionScan read 26 of Veraxa Biotech AG - Post de-SPAC's SEC filings and found 3 warrant series, 1 convertible, 1 equity line, 2 S-1 registrations and 3 completed offerings on file for VRXA. The latest dilution event on file is a registration statement on Aug 6, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
VRXA
Pre-revenue biotech securing cash runway
Snapshot
Veraxa Biotech is a clinical-stage company developing cancer therapies. Following its merger with Voyager Acquisition Corp, the company reported a FY 2025 net loss of CHF 66.6 million, largely due to CHF 52.7 million in stock-based compensation.
What's Happening Right Now
- : VRXA issued a business update outlining a strategic pivot to focus resources on its proprietary BiTAC platform and monetize non-core assets to fund growth.
- : The company partnered with ATUM to initiate cell line development for its lead BiTAC-TCE program, aiming to advance the candidate toward regulatory submission.
- : VRXA expanded its R&D hub in Heidelberg, Germany, increasing laboratory space by over 60% to support its advancing programs.
- : The company established proof-of-concept for its BiTAC-ADC technology platform, demonstrating the ability to discriminate between cancer and healthy cells.
Raise routes on file: effective S-1 + active equity line · latest dilution event 89 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Aug 6, 2026 · Registration
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Effective
S-1 · resale registration
Issued 2026
Proposed maximum
Shares registered
- Filed
- Effective
Public Warrants (former SPAC Public Warrants, VRXAW)
Issued 2026
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Private Warrants (former SPAC Private Placement Warrants)
Issued 2026
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2026
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Equity line
Issued 2026
Commitment
Sold to date
Remaining
- Agreement date
- Term ends
- Discount
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your VRXA trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
